The Pharmaceutical Research and Manufacturers of America want FDA to take the lead on assessing whether Risk Evaluation and Mitigation Strategies place an undue burden on the health care system.
The burden of evaluating that burden rests with the agency, PhRMA Assistant General Counsel Sarah Spurgeon told the agency during its recent